PL3994

Palatin Technologies, Inc · Phase 2 active Small molecule

At a glance

Generic name	PL3994
Sponsor	Palatin Technologies, Inc
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects (PHASE2)
Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma (PHASE2)
Safety Study of Subcutaneously Administered PL-3994 in Subjects With Controlled Hypertension (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PL3994 CI brief — competitive landscape report
PL3994 updates RSS · CI watch RSS
Palatin Technologies, Inc portfolio CI